What does menopause have to do with liver health?
We asked Dr. Michelle Jacobson, Co-Founder and Medical Director at Coven Women’s Health, to break down the connection between liver disease and women’s health, and to share how you can support your liver through the hormonal changes of midlife.
When we think about menopause, most women immediately think about hot flashes, sleep disruption, mood changes, or weight gain. Very few think about the liver.
And yet, emerging research suggests that the hormonal changes of menopause may significantly influence liver health and metabolic disease risk. As we begin to better understand the interconnectedness of hormones, metabolism, inflammation, and cardiovascular health, the liver is increasingly becoming part of the menopause conversation.
The challenge is that liver disease is often silent. Many women may develop early metabolic dysfunction-associated steatotic liver disease (MASLD) without any symptoms at all.
By the time symptoms appear, disease may already be advanced.
How Do Hormonal Changes Affect Liver Health?
The liver is deeply involved in hormone metabolism, insulin regulation, cholesterol handling, and inflammatory signaling. Estrogen, in particular, appears to play a protective metabolic role.
During the reproductive years, estrogen helps:
- Improve insulin sensitivity
- Regulate fat distribution
- Reduce visceral fat accumulation
- Support healthy lipid metabolism
- Reduce inflammatory signaling
As estrogen levels decline during perimenopause and menopause, we often see:
- Increased abdominal/visceral fat
- Rising insulin resistance
- Higher triglycerides
- Worsening cholesterol profiles
- Increased systemic inflammation
These changes create the perfect environment for fat accumulation within the liver.
Research suggests that postmenopausal women have a significantly higher prevalence of MASLD compared with premenopausal women, even after accounting for age and body weight. Some studies also suggest that earlier menopause may be associated with higher risk of liver fibrosis progression.
Importantly, liver disease risk is not simply about weight. Many women who are active, seemingly “healthy,” and not living in larger bodies can still develop metabolic dysfunction and MASLD during the menopause transition.
This is one reason why menopause care must evolve beyond simply treating symptoms. Menopause is a cardiometabolic transition, and the liver is part of that story.
Why Liver Disease Is Often Missed in Women?
One of the biggest problems with liver disease is that it can remain silent for years.
Women may assume symptoms are “just menopause,” while clinicians may not immediately think about liver health in midlife women.
Potential warning signs can include:
- Increasing abdominal weight gain
- Fatigue or reduced energy
- Elevated cholesterol or triglycerides
- Rising blood sugar or prediabetes
- Sleep disruption
- High blood pressure
- New insulin resistance
- Mildly elevated liver enzymes on routine bloodwork
More advanced liver disease may cause:
- Persistent right upper abdominal discomfort
- Swelling/bloating
- Easy bruising
- Yellowing of the skin or eyes
- Significant fatigue or muscle loss
But many women with fatty liver disease have completely normal liver enzymes. That’s important. A “normal” blood test does not always rule out early disease.
Other Hormonal Stages That Affect Liver Health
Menopause is not the only hormonal transition that matters.
Pregnancy
Pregnancy is a major metabolic stress test. Conditions such as gestational diabetes, preeclampsia, and cholestasis of pregnancy are associated with future cardiometabolic and liver disease risk later in life.
Women who experienced gestational diabetes or hypertensive disorders of pregnancy should view this as important long-term health information, not simply a pregnancy complication that “went away.”
Perimenopause
Perimenopause may be one of the highest-risk periods metabolically because hormonal fluctuations become highly unpredictable.
Women often notice:
- Central weight gain
- Worsening insulin resistance
- Sleep disruption
- Reduced exercise recovery
- Changes in appetite regulation
These shifts can contribute to worsening metabolic health years before the final menstrual period.
Hormonal Birth Control
Most hormonal contraception is safe for the liver in healthy individuals, but certain liver conditions may influence contraceptive choice.
Women with the following conditions should discuss contraception options carefully with their physician:
- Active liver disease
- Estrogen sensitive Liver tumors (such as hepatic adenomas)
- Cholestatic disorders
- Significant cirrhosis
Importantly, modern low-dose hormonal contraception is very different from older formulations, and many fears surrounding hormonal therapy are outdated or oversimplified.
What About Menopausal Hormone Therapy (MHT) and the Liver?
One area that creates enormous confusion for women is whether menopausal hormone therapy is “bad for the liver.”
The short answer is for most healthy women, standard menopausal hormone therapy is not considered harmful to the liver, and in some cases may even have favorable metabolic effects.
In fact, estrogen appears to play an important role in protecting against visceral fat accumulation, insulin resistance, and metabolic dysfunction, which are key drivers of fatty liver disease.
Some observational studies suggest that menopausal hormone therapy may be associated with:
- Reduced liver fat accumulation
- Improved insulin sensitivity
- Better lipid profiles
- Lower rates of metabolic syndrome
That said, the relationship is nuanced. The type of hormone therapy, route of administration, and an individual woman’s underlying health risks all matter. For example:
- Oral estrogen undergoes first-pass metabolism through the liver, which can influence clotting factors, triglycerides, and inflammatory markers.
- Transdermal estrogen (patches, gels) largely bypasses first-pass liver metabolism and may be preferable in women with certain metabolic or cardiovascular risk factors in lower doses.
- Women with active liver disease, severe cirrhosis, unexplained liver dysfunction, or certain rare liver tumors may not be candidates for some forms of hormone therapy.
This is where individualized care becomes critical.
Another important myth is the idea that menopause-related weight gain or metabolic dysfunction is simply “inevitable aging.” Hormonal changes are biologically significant, and appropriately selected menopausal hormone therapy may help improve body composition, sleep, insulin sensitivity, and overall metabolic health in some women.
What Questions Should Women in Their 40s and 50s Ask Their Doctor?
Many women have never discussed liver health with their healthcare provider. Midlife is the right time to start.
Important questions include:
- Am I showing signs of insulin resistance or metabolic syndrome?
- Should my liver enzymes or metabolic markers be monitored?
- Do I have risk factors for fatty liver disease?
- Does my pregnancy history increase my future metabolic risk?
- How does menopause affect my cardiovascular and liver health?
- Could my medications or alcohol intake affect my liver?
- Would imaging or further assessment ever be appropriate?
Women should also be aware of their:
- Blood pressure
- Waist circumference
- Lipid profile
- Hemoglobin A1c
- Family history of diabetes, liver disease, and cardiovascular disease
Menopause care should not occur in isolation from metabolic health.
What Lifestyle Changes Help Protect Liver Health?
The encouraging news is that many of the interventions that support menopause health also support liver health.
The strongest evidence supports:
- Regular physical activity, particularly resistance training
- Maintaining muscle mass
- Mediterranean-style dietary patterns
- Reducing processed foods
- Improving sleep quality
- Managing stress
- Limiting excessive alcohol intake
- Addressing insulin resistance early
- Treating sleep apnea when present
Even modest weight reduction in patients with fatty liver disease can improve liver fat accumulation and inflammation.
But this conversation should never become reductive or shame based. Women do not “cause” menopause-related metabolic shifts through lack of willpower. Hormonal biology matters.
One Misconception I Wish More Women Knew
One of the biggest misconceptions is that liver disease only affects people who drink heavily. In reality, MASLD is increasingly common and is tightly connected to insulin resistance, visceral fat, inflammation, and hormonal change.
Another misconception is that menopause is simply about symptoms. Menopause is a major physiologic transition that affects cardiovascular, metabolic, bone, brain, and liver health. It’s crucial we stop treating it like a niche quality-of-life issue.
Why Has This Connection Been So Under-Recognized?
Historically, women’s health research has focused heavily on reproduction, fertility, and pregnancy, while cardiometabolic disease in women has been under-recognized and underfunded. Women were also excluded from many major clinical trials for decades.
As a result, we are only now beginning to fully appreciate how hormonal transitions influence long-term disease risk across multiple organ systems, including the liver.
There is also a tendency to fragment women’s healthcare into silos:
- Gynecology
- Endocrinology
- Cardiology
- Hepatology
- Primary care
But the body does not function in silos. The future of menopause care must become more integrated, evidence-based, and prevention-focused. Midlife is not simply a time to manage symptoms. It is an opportunity to identify risk early, protect long-term health, and help women thrive for decades beyond menopause. Women deserve better than discovering these connections only after disease has already developed.
